首页> 外文期刊>Molecular therapy: the journal of the American Society of Gene Therapy >Modulation of CD8 + T cell responses to AAV vectors with IgG-derived MHC class II epitopes
【24h】

Modulation of CD8 + T cell responses to AAV vectors with IgG-derived MHC class II epitopes

机译:用IgG衍生的MHC II类抗原决定簇调节CD8 + T细胞对AAV载体的应答

获取原文
获取原文并翻译 | 示例
           

摘要

Immune responses directed against viral capsid proteins constitute a main safety concern in the use of adeno-associated virus (AAV) as gene transfer vectors in humans. Pharmacological immunosuppression has been proposed as a solution to the problem; however, the approach suffers from several potential limitations. Using MHC class II epitopes initially identified within human IgG, named Tregitopes, we showed that it is possible to modulate CD8 + T cell responses to several viral antigens in vitro. We showed that incubation of peripheral blood mononuclear cells with these epitopes triggers proliferation of CD4 + CD25 + FoxP3 + T cells that suppress killing of target cells loaded with MHC class I antigens in an antigen-specific fashion, through a mechanism that seems to require cell-to-cell contact. Expression of a construct encoding for the AAV capsid structural protein fused to Tregitopes resulted in reduction of CD8 + T cell reactivity against the AAV capsid following immunization with an adenoviral vector expressing capsid. This was accompanied by an increase in frequency of CD4 + CD25 + FoxP3 + T cells in spleens and lower levels of inflammatory infiltrates in injected tissues. This proof-of-concept study demonstrates modulation of CD8 + T cell reactivity to an antigen using regulatory T cell epitopes is possible.
机译:在使用腺相关病毒(AAV)作为人类基因转移载体时,针对病毒衣壳蛋白的免疫应答构成了主要的安全隐患。已提出药理免疫抑制作为该问题的解决方案。但是,该方法存在一些潜在的局限性。使用最初在人IgG中识别的MHC II类表位(称为Tregitopes),我们表明可以在体外调节CD8 + T细胞对几种病毒抗原的反应。我们表明,将外周血单核细胞与这些表位一起孵育会触发CD4 + CD25 + FoxP3 + T细胞的增殖,从而通过一种似乎需要细胞的机制抑制以抗原特异性方式杀死载有MHC I类抗原的靶细胞的杀伤。到单元的联系。用表达衣壳的腺病毒载体免疫后,编码融合到Tregitopes的AAV衣壳结构蛋白的构建体的表达导致CD8 + T细胞对AAV衣壳的反应性降低。这伴随着脾脏中CD4 + CD25 + FoxP3 + T细胞频率的增加和注射组织中炎性浸润水平的降低。这项概念验证研究表明,使用调节性T细胞表位调节CD8 + T细胞对抗原的反应性是可能的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号